About Us

Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders.

Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is referred to as the Blüm^TM Study. Our pipeline also includes clinical-stage and preclinical programs for treating ADHD, Parkinson’s, schizophrenia and addiction.

The reason why we come to work every day is simple: we are motivated first and foremost by our desire to understand and address the needs of patients and their families.

Building a Vision to Break Convention

Disruptive technology can create change. Novel methods can be used to solve problems and dramatically improve lives in simple, elegant ways.

This disruption is at the core of our vision at Curemark. Our founder, Joan Fallon, worked tirelessly to develop a disruptive breakthrough in the field of autism research after studying a number of her patients affected by the disease. She founded Curemark to continue making discoveries and working to change the paradigm for medical research. Because we put the patient first, in everything we do.

This patient-centric approach is leading to incredible findings. Our clinical program for Autism has met the primary and secondary endpoints needed to pass its clinical trials and has become fast-tracked by the FDA, while our ADHD clinical program continues to make progress towards approval for market.

Learn More

MANAGEMENT

To develop breakthrough research and treatments, Curemark relies on the support of some of the strongest minds in the industry. Our management offers a wealth of experience from a medical, operational and biotechnological standpoint. This gives our company a unique position to excel at what we do.

joan-fallon-curemark — DR. JOAN FALLON

Founder and CEO

DR. JOAN FALLON

Founder and CEO

Dr. Fallon began her research on Autism and related disorders over 20 years ago and founded Curemark as a platform to develop product candidates to address her findings. Dr. Fallon has both clinical expertise and academic experience—the former from running a private practice specializing in pediatric development, and the latter as an Assistant Professor of Natural Sciences and Mathematics at Yeshiva University.

Dr. Fallon has played an integral role in two very successful (and unprecedented) medical ventures. She was an Oxford Health Plans board member and helped achieve underwriting authority from New York State, for alternative and complementary medicine where none had yet existed. She also helped implement a cost-effective, interdisciplinary health plan for Oxford that increased the level of quality care for all children enrolled there. Dr. Fallon has written numerous scholarly articles, lectured around the world on developmental problems in the pediatric population and served on the Board of Directors of the ICA and Kentuckiana Children’s Center. She serves as a Senior Advisor to the Henry Crown Fellows at The Aspen Institute, as well as a Distinguished Fellow at the Athena Center for Leadership Studies at Barnard College/Columbia University. She is also a member of the Board of Trustees of Franklin & Marshall College. Dr. Fallon holds a B.A. degree from Franklin and Marshall College, a DC degree from Palmer University, and has completed the coursework for the MSc in clinical investigation from Harvard University’s joint program with Massachusetts General Hospital.

matthew_heil — MATTHEW F. HEIL, PhD

Chief Scientific Officer

MATTHEW F. HEIL, PhD

Chief Scientific Officer

Dr. Matthew F. Heil has served as Curemark’s Chief Scientific Officer since 2008. Dr. Heil is responsible for the oversight and direction of all scientific programs as well as drug formulation and manufacturing.

While a member of the Faculty of Medicine at New York Medical College (NYMC), Dr. Heil became a Principal Investigator conducting research on growth regulation in leukemia. He also served on NYMC’s Experimental Bone Marrow Transplant Team investigating new methodologies for allowing bone marrow transplants for patients who did not have a matching graft donor.

As a Senior Partner of both the Delphi Group and BioInnovators Consulting, Dr. Heil worked closely with senior management teams at biotechnology and pharmaceutical companies on product licensing, product valuation, technical due diligence and other aspects of research and product development .

Dr. Heil holds a Bachelor of Science in Biology from Loyola University in Chicago, a Master’s Degree from the University of Toronto and a Doctorate in Immunology from Syracuse University.

photo-team-3 — WILLIAM E. GANNON, JR., M.D., M.B.A.

Medical Director

WILLIAM E. GANNON, JR., M.D., M.B.A.

Medical Director

Dr. William E. Gannon, Jr., has served as Medical Director and Regulatory Affairs Advisor to Curemark since 2008. His responsibilities include oversight of the clinical and regulatory functions of Curemark’s clinical operations, including medical monitoring and clinical protocol design.

Dr. Gannon’s clinical trial experience covers a range of therapeutic areas, medical devices and biologic categories. Over the past 27 years, he has designed and led over 50 Phase I through Phase IV clinical trials around the world.

Dr. Gannon holds a Masters in Business Administration from George Washington University in Washington, DC, a Doctor of Medicine (M.D.) degree from Ross University/Case Western Reserve University and a Bachelor of Arts from The Catholic University of America in Washington, DC.

BOARD OF DIRECTORS

With a combined expertise in science, business and biopharmaceuticals, our Board of Directors is well equipped to help Curemark carry out its vision of creating innovative treatments—with only the monetary support of private investors.

DR. JOAN FALLON

Founder and CEO

KIMBELL DUNCAN

Mr. Duncan is an investment professional with over 30 years’ experience in trading, principal transactions and early-stage venture investing. He began his career as a trader at Goldman Sachs in 1987, moving to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities. He has been an active angel investor since 2006, focusing on equity investments in promising, early-stage biotechnology companies, including Infirst Healthcare Limited, Pharmajet Ltd, Peptcell Limited and Curemark LLC. He sits on the board of each of his portfolio companies. He co-founded Rush Foundation in 2010, a charity focused on funding innovative solutions in the fight against the HIV pandemic in sub-Saharan Africa. Kim holds a BS in Electrical and Electronics Engineering from Yale University, a MS in Biotechnology from Georgetown University and is currently a candidate for PhD in Pharmacology and Physiology from Georgetown University.